Status:
TERMINATED
Hypertension in Breast Cancer Patients Receiving Bevacizumab
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
Brigham and Women's Hospital
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This research study will look at the effect of an anti-angiogenesis medication called Bevacizumab on blood vessels. Anti-angiogenesis medicines fight cancer by cutting off a tumor's blood supply, star...
Detailed Description
* Participants will begin this research study within 14 days of starting Bevacizumab, either as part of standard treatment or as part of another clinical trial. * Participants will have an ultrasound ...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed breast cancer
- Must be starting combination treatment with bevacizumab and chemotherapy. Treatment may not have already started. Patients may receive therapy either on or off of a clinical trial.
- Any number of prior chemotherapy or biological therapy regimens is acceptable.
- Either no history of hypertension, defined as Blood Pressure \<140/90mm Hg on no antihypertensive therapy, or medically controlled pre-existing hypertension, defined as Blood Pressure \< 140/90mm HG on one non-angiotensin converting enzyme inhibitor (ACE-I) or non-angiotensin receptor blocking (ARB) medication.
Exclusion
- History of uncontrolled hypertension within the previous 6 months
- Inability to assess blood pressure or have prolonged blood pressure cuff inflation due to history of bilateral lymph node dissections, presence of an indwelling venous access device, or other condition
- Concurrent use of a statin medication
- Systolic blood pressure \< 100mm Hg
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00674011
Start Date
January 1 2008
End Date
September 1 2010
Last Update
May 6 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215